|1.||Barrett, P Hugh R: 19 articles (05/2015 - 03/2002)|
|2.||Tsimikas, Sotirios: 18 articles (04/2015 - 09/2004)|
|3.||Watts, Gerald F: 18 articles (05/2010 - 02/2002)|
|4.||Chan, Dick C: 17 articles (05/2010 - 02/2002)|
|5.||Nilsson, Jan: 14 articles (09/2015 - 05/2003)|
|6.||Witztum, Joseph L: 12 articles (04/2015 - 09/2004)|
|7.||Fredrikson, Gunilla Nordin: 11 articles (09/2015 - 05/2003)|
|8.||Shah, Prediman K: 8 articles (01/2015 - 05/2003)|
|9.||Sántha, Miklós: 8 articles (01/2015 - 09/2006)|
|10.||Hamsten, Anders: 7 articles (09/2014 - 08/2007)|
11/01/2003 - "The evidence of a regulation of apoB-100 structure by a physiological ligand opens new perspectives in the study of the biological addressing of the LDL particle and suggests a novel rationale in the search for mechanisms underlying the beneficial role of E2 in decreasing the risk of early lesions in atherosclerosis."
05/01/2003 - "These studies have identified peptide sequences in apoB-100 that induce immune responses, which inhibits atherosclerosis. "
01/01/2015 - "The apolipoprotein B-100 (ApoB-100) transgenic mouse line is a model of human atherosclerosis. "
08/01/2012 - "To use this approach for atherosclerosis, which requires a sensitizing mutation, we bred human apolipoprotein B-100 transgenic mice with 22 different inbred strains to produce F1 heterozygotes. "
07/01/2011 - "The chimeric protein containing hHSP60 peptide was more efficient than that containing apoB-100 peptide for inhibiting atherosclerosis. "
|2.||Cardiovascular Diseases (Cardiovascular Disease)
05/01/2003 - "In prospective clinical studies, antibody levels against several aldehyde-modified apoB-100 sites were associated with cardiovascular disease in this age group. "
10/05/2004 - "Thus, passive immunization against MDA-modified apoB-100 peptide sequences may represent a novel therapeutic approach for prevention and treatment of cardiovascular disease."
08/01/2001 - "Familial defective apolipoprotein B-100, a dominantly inherited form of hypercholesterolemia caused by a single Arg3500Gln mutation, is silent in childhood but may confer a high risk of cardiovascular disease in adulthood. "
01/01/2014 - "The present study provides further evidence of involvement of autoantibodies against native and MDA-modified apoB-100 peptide 210 in cardiovascular disease in humans and demonstrates that these associations are present already at a subclinical stage of the disease."
05/01/2005 - "High levels of plasma apolipoprotein B-100 (apoB-100), the principal apolipoprotein of LDL, are associated with cardiovascular disease. "
|3.||Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
01/01/2011 - "To study whether subjects with a molecular genetic diagnosis of familial hypercholesterolemia (FH) or familial defective apoB-100 (FDB) are being adequately treated. "
10/01/2007 - "The objective of this study was to examine frequency of familial defective apo-B-100 (FDB, R3500Q mutation) in probands with the phenotype of familial hypercholesterolemia (FH) and in the general population of 40-year-old subjects in Slovakia and to characterize their lipid and clinical criteria and to compare the frequency of FDB with other populations. "
01/01/2011 - "Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated."
11/01/2008 - "Of the 23 subjects with autosomal dominant hypercholesterolemia, four subjects (17.4%) were heterozygous for mutations in the apoB-100 gene. "
10/01/2007 - "H3543Y mutation of apoB-100 in patients with phenotype of familial hypercholesterolemia."
07/01/2015 - "SPF reduces obesity-linked MetS features in LDLR(-/-)/ApoB(100/100) mice. "
03/01/2000 - "Genotypic associations of the hepatic secretion of VLDL apolipoprotein B-100 in obesity."
02/01/1995 - "Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: a stable isotope study."
01/01/2012 - "The second aspect discussed in this commentary, regarding hyperlipidaemia in obesity and diabetes, concerns the argument that apolipoprotein B-100 level or non-HDL cholesterol should specifically be measured for screening and treatment targets."
10/01/2014 - "Association between skeletal muscle fat content and very-low-density lipoprotein-apolipoprotein B-100 transport in obesity: effect of weight loss."
|5.||Hepatocellular Carcinoma (Hepatoma)
01/01/2011 - "The hepatoma HepG2 cell line has been the cell line of choice for the study of synthesis and secretion of human apoB-100. "
10/01/2008 - "Apolipoprotein B-100 (apoB-100) is an ERAD substrate in liver cells, including the human hepatoma, HepG2. "
01/01/1996 - "126.96.36.199), on the lipid and on the apoB-100 secretion rate from a human hepatoma cell line (HepG2). "
10/15/1986 - "The synthesis and secretion of apolipoprotein B-100 (apoB-100) have been studied in a human hepatoma cell line, the Hep G2 cells. "
07/01/2001 - "We used the HepG2 hepatoma cell line to: (1) determine the time required until levels of secreted apo B-100 and TG declined significantly, (2) examine the relation to the mass of cellular cholesteryl ester (CE) and (3) test microsomal triglyceride transfer protein (MTP) activity which leads to decreased apo B-100 production. "
|1.||Apolipoproteins B (ApoB)
|4.||Apolipoprotein A-I (Apolipoprotein A1)
|6.||LDL Lipoproteins (beta Lipoproteins)
|8.||Catechin (Z 7300)
|9.||epigallocatechin gallate (epigallocatechin-3-gallate)
|1.||Renal Dialysis (Hemodialysis)
|2.||Drug Therapy (Chemotherapy)
|3.||Fat-Restricted Diet (Diet, Fat Restricted)